Clinical Trials Logo

Filter by:
NCT ID: NCT05200364 Active, not recruiting - Ovarian Cancer Clinical Trials

A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer

Start date: March 22, 2022
Phase: Phase 1
Study type: Interventional

Phase 1 trial to study the safety, pharmacokinetic and Preliminary Efficacy of STRO-002 in combination with Bevacizumab.

NCT ID: NCT05200143 Active, not recruiting - Clinical trials for Refractory Cutaneous Melanoma

Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma

Start date: June 8, 2022
Phase: Phase 2
Study type: Interventional

The primary objective of this clinical trial is to evaluate the clinical efficacy and progression free survival of the triplet combination of ipilimumab + nivolumab + cabozantinib in patients with anti-PD-1/PD-L1 refractory metastatic cutaneous melanoma.

NCT ID: NCT05199948 Active, not recruiting - Clinical trials for Nonalcoholic Fatty Liver

Weight, Energy, Lipids, and the Liver (WELL) Study

Start date: May 2, 2022
Phase: N/A
Study type: Interventional

The research study is a parallel arm, randomized placebo-controlled clinical trial designed to assess changes in hepatic lipid accumulation, visceral adipose tissue and postprandial lipid, markers of inflammation and energy metabolism in participants who consume 3 study foods per day for 16 week, while maintaining their body weight.

NCT ID: NCT05199584 Active, not recruiting - Clinical trials for Solid Tumors With PTCH1 Loss-of-function Mutations

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Start date: May 24, 2022
Phase: Phase 2
Study type: Interventional

This study employs a 2-stage design that aims to evaluate the efficacy and safety of ENV- 101, a potent Hedgehog (Hh) pathway inhibitor, in patients with refractory advanced solid tumors characterized by loss of function (LOF) mutations in the Patched-1 (PTCH1) gene. Stage 1 of this study will enroll approximately 44 patients randomized between two dose levels. As appropriate, Stage 2 of the study will expand enrollment based on the results of Stage 1.

NCT ID: NCT05199467 Active, not recruiting - Clinical trials for Veteran Reintegration

Health Coaching: A Pilot Trial Among Reintegrating Veterans

Start date: November 1, 2022
Phase: N/A
Study type: Interventional

Health coaches help people focus on goals, identify strengths and values, and work towards building the life they wish to live. Health coaching may be especially helpful for people navigating a life transition, such as Veterans who recently separated from military service (i.e., reintegrating Veterans). In this pilot trial the investigators will 1) examine the feasibility of study procedures and acceptability of health coaching among reintegrating Veterans, 2) evaluate measures for suitability in a future trial that will examine efficacy of the intervention, 3) determine barriers and facilitators to implementing the intervention among reintegrating Veterans.

NCT ID: NCT05199337 Active, not recruiting - Amyloidosis Clinical Trials

Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis

Start date: November 30, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single arm, Open-Label, Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis.

NCT ID: NCT05199272 Active, not recruiting - Solid Tumor Clinical Trials

A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

Start date: December 29, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a first-in-human open-label Phase 1/2a study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of 23ME-00610 given by intravenous infusion in patients with advanced solid malignancies who have progressed on all available standard therapies

NCT ID: NCT05199233 Active, not recruiting - COVID-19 Clinical Trials

Mindfulness Intervention for Post-Covid Symptoms

Start date: June 1, 2022
Phase: N/A
Study type: Interventional

The purpose of this research is to study if post-Covid patients using a wearable brain sensing wellness device (Muse-S) to learn meditation practice during a time where they are experiencing lengthy Covid symptoms will help in decreasing stress and anxiety.

NCT ID: NCT05198934 Active, not recruiting - Clinical trials for Colorectal Cancer (CRC)

Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation

CodeBreak300
Start date: April 19, 2022
Phase: Phase 3
Study type: Interventional

The aim of the study is to compare progression-free survival (PFS) in previously treated participants with Kirsten rat sarcoma (KRAS) p.G12C mutated colorectal cancer (CRC) receiving sotorasib 240 mg once daily (QD) and panitumumab vs investigator's choice (trifluridine and tipiracil, or regorafenib), and sotorasib 960 mg QD and panitumumab vs investigator's choice (trifluridine and tipiracil, or regorafenib).

NCT ID: NCT05198284 Active, not recruiting - Clinical trials for Chronic Kidney Diseases

Prospective Decision Impact Clinical Utility Trial of KidneyIntelX

Start date: November 1, 2021
Phase:
Study type: Observational

The clinical utility trial is designed to evaluate how the results of KidneyIntelX test / platform impacts on the clinical management of type 2 diabetes patients identified as increased risk for rapid kidney function decline within 5-years.